

Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12545.

Dated: April 8, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-9866 Filed 4-14-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of AIDS Research, Office of the Director; Notice of Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Office of AIDS Research Advisory Council on April 29, 1998, National Institutes of Health, Building 31, C Wing, Conference Room 6, 9000 Rockville Pike, Bethesda, Maryland 20892.

The meeting will be open to the public from 9:00 a.m. until adjournment. Attendance by the public will be limited to space available. The purpose of the meeting will be to review and obtain the Council's advice on the following agenda items: (1) a report of the Acting Director, OAR; (2) a review of the FY 2000 NIH Plan for HIV-Related Research; (3) updates from the AIDS Vaccine Research Committee, the Prevention Science Working Group, and the Therapeutics Research Working Group; and (4) an overview of international NIH AIDS research programs.

Copies of the meeting agenda and roster of council members will be furnished upon request by Ms. Deborah Kraut, Program Analyst, Office of AIDS Research (OAR), 9000 Rockville Pike, Building 31, Room 4B62, National Institutes of Health, Bethesda, Maryland, Telephone (301) 402-8655 and Dr. Robert W. Eisinger, Head, Science Policy and Analysis Section, OAR, Telephone (301) 402-8655 will provide substantive program information.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Kraut no later than April 22, 1998.

Dated: April 9, 1998.

LaVerne Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-9984 Filed 4-14-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Purpose/Agenda: To review and evaluate contract proposals.

Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel.

Date of Meeting: April 15, 1998 (Telephone Conference).

Time: 11:00 a.m.

Place of Meeting: Willco Building, 6000 Executive Boulevard, Suite 400, Rockville, MD 20892-7003.

Contact Person: Sean O'Rourke, 6000 Executive Boulevard, Suite 409, Rockville, MD 20892-7003, 301-443-2861.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance, Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; and 93.891, Alcohol Research Center Grants; National Institutes of Health)

Dated: April 9, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-9992 Filed 4-14-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Phase II Study of Arsenic Trioxide in Leukemia Telephone Conference Call.

Date: April 27, 1998.

Time: 12:30 p.m. to Adjournment.

Place: National Cancer Institute, Executive Plaza North, Room 635C, 6130 Executive Boulevard, Bethesda, MD 20892.

Contact Person: David Irwin, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 635C, 6130 Executive Boulevard, MSC 7408, Bethesda, MD 20892-7408, Telephone: 301/402-0371.

Purpose/Agenda: To review, discuss and evaluate grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: April 9, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-9983 Filed 4-14-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to Section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a teleconference meeting of the Advisory Committee to the Director, National Cancer Institute.

The entire meeting will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Linda Quick-Cameron, Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 609, 6130 Executive Blvd., MSC 7410, Bethesda, MD 20892-7410 (301/496-5708). A summary of the